TY - JOUR
T1 - Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer
AU - Coccaro, Mariarosa
AU - Tartarone, Alfredo
AU - Romano, Gianpiero
AU - Ardito, Raffaele
AU - Di Renzo, Nicola
PY - 2005/7
Y1 - 2005/7
N2 - Objective: The aim of this phase I study was to find the maximum tolerated dose of weekly docetaxel in association with estramustine in hormone-refractory prostate cancer. Methods: Eleven patients with hormone-refractory prostate cancer were treated with escalating weekly doses of docetaxel (level I, 3 patients, 30 mg/m2; level II, 3 patients, 35 mg/m2, level III, 3 patients, 40 mg/m2; level IV, 2 patients, 45 mg/m2) associated with fixed dosage of estramuscine (840 mg/day). Results: In level I, there was only one episode of grade 3 neutropenia; grade 1 nausea and vomiting were registered in 1 patient; in 1 patient mild edema of the lower limbs was noted. In level II, grade 2 stomatitis and grade 1 sensory symptoms occurred in 1 patient, and grade 1 edema in 1 case. In level III, grade 2 edema was noted in 2 patients, damage to nails in 1 patient, asthenia in 1 patient, grade 1 neuropathy in 2 patients, and grade 1 nausea in 1 patient. In level IV, grade 2 edema was present in 1 patient, grade 3 edema in 1 patient, changes with fall of nails and grade 2 erythema of face in 2 patients, asthenia in 2 patients, grade 1 neuropathy in both patients. Nine patients had a more than a 50% decrease in PSA after 2 cycles of therapy. Conclusions: The results of the study suggest a good tolerability of weekly 35 mg/m2 dpcetaxel in hormone-refractory prostate cancer in association with estramustine.
AB - Objective: The aim of this phase I study was to find the maximum tolerated dose of weekly docetaxel in association with estramustine in hormone-refractory prostate cancer. Methods: Eleven patients with hormone-refractory prostate cancer were treated with escalating weekly doses of docetaxel (level I, 3 patients, 30 mg/m2; level II, 3 patients, 35 mg/m2, level III, 3 patients, 40 mg/m2; level IV, 2 patients, 45 mg/m2) associated with fixed dosage of estramuscine (840 mg/day). Results: In level I, there was only one episode of grade 3 neutropenia; grade 1 nausea and vomiting were registered in 1 patient; in 1 patient mild edema of the lower limbs was noted. In level II, grade 2 stomatitis and grade 1 sensory symptoms occurred in 1 patient, and grade 1 edema in 1 case. In level III, grade 2 edema was noted in 2 patients, damage to nails in 1 patient, asthenia in 1 patient, grade 1 neuropathy in 2 patients, and grade 1 nausea in 1 patient. In level IV, grade 2 edema was present in 1 patient, grade 3 edema in 1 patient, changes with fall of nails and grade 2 erythema of face in 2 patients, asthenia in 2 patients, grade 1 neuropathy in both patients. Nine patients had a more than a 50% decrease in PSA after 2 cycles of therapy. Conclusions: The results of the study suggest a good tolerability of weekly 35 mg/m2 dpcetaxel in hormone-refractory prostate cancer in association with estramustine.
KW - Hormonorefractory
KW - Prostate cancer
KW - Weekly docetaxel
UR - http://www.scopus.com/inward/record.url?scp=26444610040&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=26444610040&partnerID=8YFLogxK
M3 - Article
C2 - 16277095
AN - SCOPUS:26444610040
VL - 91
SP - 314
EP - 316
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 4
ER -